3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
18
Lymphoma, Large B-Cell, Diffuse
16
Leukemia, Myeloid, Acute
16
Hodgkin Disease
16
Lymphoma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Non-Hodgkin
12
Lung Neoplasms
12
Lymphoma, Mantle-Cell
10
Lymphoma, Follicular
10
Leukemia
10
Lymphoma, B-Cell
7
Carcinoma, Non-Small-Cell Lung
7
Burkitt Lymphoma
6
Recurrence
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell, Marginal Zone
4
Congenital Abnormalities
4
Waldenstrom Macroglobulinemia
3
Plasmablastic Lymphoma
3
Ovarian Neoplasms
3
Lymphoma, Primary Effusion
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Immunoblastic Lymphadenopathy
3
Interventions
talimogene laherparepvec
1
rilotumumab
1
ganitumab
1
camrelizumab
1
Thiostrepton
1
Silver Nitrate
1
Nivolumab
1
Etoposide
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pleural Effusion, Malignant
×
Etoposide
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts